Core Insights - Bolt Biotherapeutics is set to present data from its Phase 1 dose-escalation clinical study of BDC-3042 at the AACR Annual Meeting in April 2025, focusing on patients with advanced cancers [1][2] Group 1: Clinical Study Details - BDC-3042 is a proprietary agonist antibody targeting dectin-2, an immune-activating receptor found in tumor-associated macrophages, and is being evaluated in patients with metastatic or unresectable solid tumors, including non-small cell lung cancer (NSCLC) [2][7] - The Phase 1 clinical study is a single-agent, dose-escalation trial assessing the safety and efficacy of BDC-3042 [2][7] Group 2: Presentation Information - The poster presentation titled "BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study" will be presented by Dr. Ecaterina E. Dumbrava on April 29, 2025 [4] - Additional presentations will include preclinical data on Boltbody™ ISACs targeting CEA and PD-L1, showcasing the company's innovative approaches to cancer treatment [2][4] Group 3: Boltbody™ ISAC Platform - The Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune stimulants to enhance anti-cancer responses by activating myeloid cells [5] - This platform aims to create a robust immune response within the tumor microenvironment, potentially leading to durable therapeutic outcomes for cancer patients [5] Group 4: Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment, leveraging expertise in myeloid biology and cancer drug development [6][7] - The company's pipeline includes BDC-3042 and BDC-4182, with the latter expected to enter clinical trials in the second quarter of 2025 [7]
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025